



PRESS RELEASE

TEOXANE REVEALS NEW STUDY ON SEQUENTIAL TREATMENT USING HYALURONIC ACID INJECTABLES TO ENHANCE SKIN QUALITY

Geneva, Switzerland - July 15th, 2025 - Teoxane is excited to announce the publication of a new study titled "Enhancing Skin Quality with a Sequential Treatment Using Two Hyaluronic Acid Dermal Fillers: A Prospective, Multicenter, Interventional Study" in the Aesthetic Surgery Journal. This study highlights the effectiveness and safety of a sequential treatment approach using two hyaluronic acid (HA) products to improve skin quality.

"The SKINQARE study demonstrates the value of a sequential filler approach. With RHA® 1, patients experienced firmer, smoother, and more hydrated skin, while the addition of RHA® R1 helped to prolong these improvements over time. Together, this strategy supports clinically meaningful and sustained enhancement of overall skin quality" explains Dr. Paula Rosso

a mis en forme : Anglais (Royaume-Uni)

Study design

The SKINQARE study was a prospective, multicenter, low-interventional, open-label study conducted across multiple centers in Spain, aiming to evaluate the performance and safety of a sequential treatment using two HA-based products in patients seeking improvement of fine lines in the face and neck areas and overall skin quality improvement.

The study used two specific HA injectables from the TEOSYAL® range. TEOSYAL® RHA 1 (RHA1) was selected for its high stretch and ability to integrate with dynamic facial movements, smoothing out superficial fine lines in targeted facial areas, thereby improving overall skin appearance and texture. TEOSYAL® Redensity 1 (R1), a non-crosslinked HA, was chosen to improve skin quality, namely skin texture, plumpness, and firmness, ultimately leading to skin redensification.

The study utilized a sequential treatment approach to achieve optimal results. RHA 1 was used for skin beautification, followed by R1 to improve skin redensification. This approach ensured holistic improvement in skin quality.

The injection techniques were chosen at the discretion of the investigator. Nevertheless, injection depths and devices were listed in the study protocol:

- Both products were injected into the dermis or in the immediate hypodermis (subcutaneous plane), depending on the device, which could be a needle or cannula.
- The maximum volume of each injected product was 6mL per session for all indications included, to prevent lumps and bumps and ensure natural-looking results.

Key findings

Primary endpoint was met, with **87%** of injections across **all treated indications** rated **«improved»** or **«much improved»** on the Global Aesthetic Improvement Scale (GAIS) after two months, exceeding the defined threshold of 70%. For smiling lines specifically, 92.7% of patients showed GAIS improvement at 2 months after RHA1.

- **Secondary endpoints supported the efficacy of RHA® 1 in smiling lines:**
- **90% GAIS improvement at 2 months**
- **Sustained patient satisfaction through 5 months**
- **Reported benefits of firmer, smoother, more hydrated skin and revitalization**
- **Objective imaging showed reductions in wrinkle thickness and volume**

Exploratory endpoints highlighted the added value of sequential treatment with RHA® 1 + RHA® R1:

- The proportion of patients in the RHA1 + R1 group who were “very satisfied” at 5 months was 2-fold greater (82%) than the RHA1-only group, and the remainder were “satisfied” (18%).
- A prolonged effect was observed for “firmness” (73.5%), “smoothness” (41.2%), and the feeling of being “refreshed” (38.2%) after the RHA1 + R1 treatment after 5 months in smiling lines.
- Objective assessments (CANFIELD system) demonstrated extended reductions in wrinkle thickness, surface area, and volume, maintained up to 5 months.

Clinical implications

Overall, both products showed consistent efficacy and safety outcomes, irrespective of the injection method used, enabling practitioners to achieve optimal aesthetic outcomes.

The sequential use of two HA-based products with distinct compositions and rheological properties offers a holistic approach to improve skin quality, specifically for the treatment of fine lines, including smiling lines. RHA1 was effective for skin beautification, whereas R1 can be used as an additional redensification step to increase patient satisfaction and prolong the effects of RHA1.

These findings confirm the use of RHA1 for skin beautification and suggest that including R1 in the treatment plan can have additional benefits for patients.

About TEOSYAL® RHA 1

TEOSYAL RHA® 1 is indicated for the correction of superficial fine wrinkles, skin cracks and depressions in the perioral region (perioral rhytids, lips including philtrum, oral commissures), in the upper face region (forehead lines), in the periorbital region (crow's feet, tear trough, eyebrows), in the midface region (smiling lines/accordion lines) and in the neck lines.

It is also indicated for the enhancement of skin quality and the correction of withered skin marked by signs of ageing in the face, neck and décolleté regions

a mis en forme : Police :(Par défaut) Century Gothic, 10 pt, Gras, Couleur de police : Texte 1

a mis en forme : Police :(Par défaut) Century Gothic, 10 pt, Gras, Couleur de police : Texte 1

a mis en forme : Police :(Par défaut) Century Gothic, 10 pt, Gras, Couleur de police : Texte 1, Anglais (États-Unis)

a mis en forme : Police :Non Gras, Anglais (États-Unis)

About TEOSYAL® PURESENSE REDENSITY 1

This injectable is formulated to nourish and restore skin quality rather than create volume. Enriched with a unique combination of hyaluronic acid, amino acids, antioxidants, vitamins, and minerals, it is designed to hydrate the skin, improve radiance, and combat signs of aging. Injected into the dermis or subcutaneously, TEOSYAL® PURESENSE REDENSITY 1 helps to smooth fine lines, enhance luminosity, and promote healthier complexion.

About Teoxane

Founded by Valérie Taupin in 2003, Teoxane Laboratories is the leading Swiss expert in the science of hyaluronic acid. For 20 years, Teoxane has pushed innovation, pioneered the future of aesthetics, and opened the door to a new world of natural, expressive, and emotive beauty. The company was founded on a singular vision: to unlock the possibilities of aesthetic treatments through high-performance dermal filler and dermocosmetics, rooted in rigorous scientific research. By consistently listening, educating and laying groundwork for a safer industry, Teoxane has shaped a new era in aesthetic medicine where small acts of beauty create dramatic changes in the lives of patients and healthcare practitioners alike.

www.teoxane.com

Code de champ modifié

Press Contact

Tiffanie Ereno – PR & Communications Manager :

t.eren@teoxane.com

press@teoxane.com

Code de champ modifié

Code de champ modifié

Medical devices for professional use only. Product indications and availability vary from country to country. Please consult product instructions locally approved for more information.

Medical devices are regulated health products bearing the CE mark, CE2797, under the Medical Device Regulation (EU) 2017/745.

Contact for materiovigilance notification: medical@teoxane.com.

Reference: Rosso P, Colina J, Jarne C, Garrigós E, Magalhães B, Da Costa MA, Poupart K. Enhancing Skin Quality With a Sequential Treatment Using Two Hyaluronic Acid Dermal Fillers: A Prospective, Multicenter, Interventional Study. *Aesthet Surg J.* 2025 Jun 13;sjaf111. doi: 10.1093/asj/sjaf111. Epub ahead of print. PMID: 40509910.